Initial Treatment and Management of Inflammatory Myopathy

Introduction to Treatment Protocols

The American College of Rheumatology recommends initiating prednisone at 0.5-1 mg/kg/day (typically 60-80 mg daily) for 2-4 weeks, then tapering systematically while starting a steroid-sparing immunosuppressive agent from day one 1, 2, 3, 4

Higher doses of prednisone (closer to 1 mg/kg) should be used for patients at high risk of relapse and low risk of adverse events, as recommended by the Mayo Clinic 1, 2
Lower doses of prednisone (closer to 0.5 mg/kg) are appropriate for patients with comorbidities that increase steroid-related complications, such as diabetes, osteoporosis, glaucoma 1, 2
The initial dose of prednisone should not exceed 30 mg/day, and doses above this threshold are strongly discouraged by the Annals of the Rheumatic Diseases 5
Initial doses of prednisone ≤7.5 mg/day are inadequate for inflammatory myopathy and should be avoided, according to the Annals of the Rheumatic Diseases 5

The American College of Rheumatology recommends initiating a steroid-sparing immunosuppressive agent on day one, as corticosteroid monotherapy fails in 86% of patients 3
Methotrexate is the first-line choice for most patients without lung disease, starting at 15 mg orally once weekly with 1 mg/day folic acid 1, 2, 3
Azathioprine is preferred for interstitial lung disease or pregnancy planning, starting at 25-50 mg weekly 1, 2
Mycophenolate mofetil is preferred for severe dermatomyositis skin disease, starting at 500 mg twice daily 1, 2, 3

The Mayo Clinic recommends beginning tapering after 2-4 weeks based on clinical response, never continuing high-dose steroids beyond this initial period 1, 2, 4
A structured taper protocol should be followed, adjusting every 2 weeks if remission is maintained 1, 2

Pulse IV methylprednisolone is indicated for patients with severe weakness, dysphagia, respiratory muscle involvement, or extensive extramuscular disease 4, 6
Additional therapies for refractory cases include IVIG, rituximab, cyclosporine, tacrolimus, and cyclophosphamide 3, 6, 7, 8

The American Academy of Pediatrics recommends starting prednisone at 2 mg/kg/day up to a maximum of 60 mg/day for juvenile dermatomyositis 7, 8, 4
Subcutaneous methotrexate should be added at 15 mg/m² weekly from treatment onset 7, 8, 4

Regular monitoring of muscle strength testing, creatine kinase levels, and screening for steroid-related complications is essential 4
Pitfalls to avoid include using corticosteroid monotherapy, delaying the start of steroid-sparing agents, and using initial prednisone doses >30 mg/day or ≤7.5 mg/day 1, 2, 3, 5

Inclusion body myositis is generally resistant to standard immunotherapy, but a trial of prednisone with methotrexate is reasonable for newly diagnosed patients 7
Intramuscular methylprednisolone is an acceptable alternative to oral glucocorticoids for patients with adherence concerns or gastrointestinal intolerance 5